Resultats de la cerca - David E. Gerber

Refinar resultats
  1. 1
    EGFR inhibition in the treatment of non‐small cell lung cancer

    EGFR inhibition in the treatment of non‐small cell lung cancer per David E. Gerber

    Publicat 2008
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Targeting the PI3K Pathway for Cancer Therapy

    Targeting the PI3K Pathway for Cancer Therapy per Navid Sadeghi, David E. Gerber

    Publicat 2012
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment

    Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment per Lorraine Pelosof, David E. Gerber

    Publicat 2010
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    ALK alterations and inhibition in lung cancer

    ALK alterations and inhibition in lung cancer per Tri Le, David E. Gerber

    Publicat 2016
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?

    Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? per Tri Le, David E. Gerber

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review

    Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review per Shaheen Khan, David E. Gerber

    Publicat 2019
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    AXL Inhibitors: Status of Clinical Development

    AXL Inhibitors: Status of Clinical Development per Sheena Bhalla, David E. Gerber

    Publicat 2023
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea

    Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea per David E. Gerber, Joan H. Schiller

    Publicat 2013
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  9. 9
    ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

    ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time per David E. Gerber, John D. Minna

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  10. 10
    ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer

    ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer per David E. Gerber, GR Oxnard, Ramaswamy Govindan

    Publicat 2015
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  11. 11
    Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy

    Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy per Sawsan Rashdan, John D. Minna, David E. Gerber

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis

    Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis per Mitchell S. von Itzstein, Shaheen Khan, David E. Gerber

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  13. 13
    Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity?

    Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity? per Jeffrey T. Yorio, Yang Xie, Jingsheng Yan, David E. Gerber

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer

    Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer per Caitlin C. Murphy, David E. Gerber, Sandi L. Pruitt

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

    BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer per Bercin Kutluk Cenik, Katherine T. Ostapoff, David E. Gerber, Rolf A. Brekken

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Prevalence of Autoimmune Disease Among Patients With Lung Cancer

    Prevalence of Autoimmune Disease Among Patients With Lung Cancer per Saad A. Khan, Sandi L. Pruitt, Lei Xuan, David E. Gerber

    Publicat 2016
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors

    Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors per David Hsiehchen, Mary Katherine Watters, Rong Lü, Yang Xie, David E. Gerber

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas1

    The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas1 per David E. Gerber, Stuart A. Grossman, Michel Zeltzman, Michele A. Parisi, Lawrence Kleinberg

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition

    Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition per Pavel A. Levin, Melissa Mayer, Sharon Hoskin, Joseph Sailors, Dwight Oliver, David E. Gerber

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Impact of Prior Cancer on Eligibility for Lung Cancer Clinical Trials

    Impact of Prior Cancer on Eligibility for Lung Cancer Clinical Trials per David E. Gerber, Andrew L. Laccetti, Lei Xuan, Ethan A. Halm, Sandi L. Pruitt

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: